New drug combo aims to knock out stomach bug in phase 3 trial
NCT ID NCT06751121
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a new triple therapy containing DWP14012 is as good as the standard treatment for eradicating H. pylori, a bacteria that can cause stomach ulcers. 461 adults with confirmed H. pylori infection took part. The main goal was to see if the infection was gone four weeks after treatment ended.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HELICOBACTER PYLORI INFECTED PATIENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a fecal transplant beat a stubborn stomach bug?
- AI eye on stomach cancer: 6,000-Person trial tests smarter scopes
- Simpler h. pylori treatment could reduce antibiotic use
- AI to predict cancer risk from gut bacteria and scans
- Stool test could replace endoscopy for h. pylori treatment decisions
- New hope against stomach bug in Antibiotic-Resistant region